T

he FDA is digging into the data on a revolutionary new approach to treating cancer. At stake: billions of dollars for pharma giant Novartis, a blockbuster race among biotech startups, and a potential breakthrough for patients with aggressive forms of cancer.

Join STAT’s Adam Feuerstein and Damian Garde plus EP Vantage’s Jacob Plieth for an all-day live blog of the make-or-break meeting, starting at 8 a.m. ET.

The live blog is now closed. You can access the archive below.

advertisement

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.